Monday, January 13, 2020 8:41:33 AM
Patents rejected and Uncle Kenny hide from us again
He was probably too busy in Thailand watching cells grow to notice.
I stated early on, a drug company just can't take a patent that has expired, and then file for a new one. One has to make new claims which are not obvious. If PMCB were allowed to get away with such nonsense, the generics would be out of business. Every drug company with a major drug on the market, due to expire, would just submit a new patent.
Then there was the idea Kenny had made new claims. Apparently the USPO thought otherwise. They initially turned it down in Jun, gave an extension in Oct so Kenny could make a supplemental filing, and then rejected in for good in Nov.
Oh, but it's designated Orphan. However it's not approved. The good news for PMCB SHs is that no one in the biotech industry is interested in the Kenny Wonder Treatment. Else, they could have made their own magic cells last Jun, encased them, and been in CTs ahead of PMCB.
Another factor is this is not 2014. It's almost 6 yrs since PMCB got their orphan designation. There are treatments for 2nd line PC patients. More are on the way in CTs. Treatments the Kenny Wonder Treatment will not be able to match. Thus, the FDA won't be cutting PMCB must slack.
All of this dovetails into the dream some Pharma is going to buy PMCB at a PPS it will take the acquirer 150 yrs to recoup or recover from. What would they be acquiring? Answer: A pile of issued stock. A large Pharma didn't get to be large by making stoopid decisions.
He was probably too busy in Thailand watching cells grow to notice.
I stated early on, a drug company just can't take a patent that has expired, and then file for a new one. One has to make new claims which are not obvious. If PMCB were allowed to get away with such nonsense, the generics would be out of business. Every drug company with a major drug on the market, due to expire, would just submit a new patent.
Then there was the idea Kenny had made new claims. Apparently the USPO thought otherwise. They initially turned it down in Jun, gave an extension in Oct so Kenny could make a supplemental filing, and then rejected in for good in Nov.
Oh, but it's designated Orphan. However it's not approved. The good news for PMCB SHs is that no one in the biotech industry is interested in the Kenny Wonder Treatment. Else, they could have made their own magic cells last Jun, encased them, and been in CTs ahead of PMCB.
Another factor is this is not 2014. It's almost 6 yrs since PMCB got their orphan designation. There are treatments for 2nd line PC patients. More are on the way in CTs. Treatments the Kenny Wonder Treatment will not be able to match. Thus, the FDA won't be cutting PMCB must slack.
All of this dovetails into the dream some Pharma is going to buy PMCB at a PPS it will take the acquirer 150 yrs to recoup or recover from. What would they be acquiring? Answer: A pile of issued stock. A large Pharma didn't get to be large by making stoopid decisions.
The Jewel of the Mind is Colored with the Hue of what it Imagines
Recent PMCB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:19:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/17/2026 07:49:54 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/09/2026 01:40:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 10:02:46 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 10:05:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/18/2025 10:04:23 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 12/15/2025 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2025 10:07:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 10:00:25 PM
- PharmaCyte Biotech stock surges following profitable exit from Femasys investment • IH Market News • 11/25/2025 03:56:47 PM
- PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment • Business Wire • 11/25/2025 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:32:29 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/18/2025 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/06/2025 09:08:43 PM
